Zymeworks Inc

NYSE:ZYME   2:31:33 PM EDT
+0.14 (+2.34%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)354.15M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$6.95 Million
Adjusted EPS-$0.97
See more estimates
10-Day MA$5.77
50-Day MA$6.18
200-Day MA$16.59
See more pivots

Zymeworks Inc Stock, NYSE:ZYME

114 East 4th Avenue, Suite 800, Vancouver, British Columbia V5T 1G4
Phone: +1.604.678.1388
Number of Employees: 458


Zymeworks, Inc. is a clinical-stage biopharmaceutical company, engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.